Does combination treatment including macitentan and/or selexipag improve non-invasive low-risk criteria in patients with pulmonary arterial hypertension?
Italian cohort with pulmonary arterial hypertension (PAH)
Macitentan and/or selexipag as a part of a combination treatment
Increase in non-invasive low-risk criteria (disease stabilization) over 12 monthssurrogate
Real-world combination therapy with macitentan and/or selexipag in PAH patients is associated with an increase in non-invasive low-risk criteria, suggesting disease stabilization over 12 months.
The INSPECTIO study supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in PAH. The increase in non-invasive low-risk criteria suggests a stabilization of disease over 12 months.
Building similarity graph...
Analyzing shared references across papers
Loading...
D'Alto et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69a7669bbadf0bb9e87ddadb — DOI: https://doi.org/10.1016/j.vph.2026.107585
Michele D'Alto
Laura Scelsi
Livio Giuliani
Vascular Pharmacology
Università Cattolica del Sacro Cuore
University of Verona
University of Bari Aldo Moro
Building similarity graph...
Analyzing shared references across papers
Loading...